SCM
TNXP icon

Superstring Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Superstring Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$812K Buy
63,648
+108
+0.2% +$1.39K 0.51% 27
2026
Q1 		$874K Buy
+63,540
New +$978K 0.62% 30

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Superstring Capital Management's TNXP Position: Q2 2026 in Review

Superstring Capital Management increased its Tonix Pharmaceuticals (TNXP) stake by 0.17% in Q2 2026, buying an estimated $1.39K and bringing the position to 63,648 shares worth $812K. The position accounts for 0.51% of the portfolio, ranked #27.

Superstring Capital Management first reported a position in TNXP in Q1 2026 and has held it in 2 quarters since. The position peaked at $874K in Q1 2026. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Superstring Capital Management held 63,648 shares of Tonix Pharmaceuticals worth $812K as of Q2 2026.
  • Superstring Capital Management bought 108 Tonix Pharmaceuticals shares in Q2 2026, an estimated $1.39K.
  • Tonix Pharmaceuticals made up 0.51% of Superstring Capital Management's portfolio in Q2 2026, its #27 holding.
  • Superstring Capital Management first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Superstring Capital Management's Tonix Pharmaceuticals position peaked at $874K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.